Eldelumab
Eldelumab is a fully human monoclonal antibody that targets chemokine ligand 10 /Interferon-γ-inducible protein-10 designed for the treatment of Crohn's disease and ulcerative colitis.
This drug was developed by Bristol-Myers Squibb and Medarex.